Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age

Antimicrobial resistance increases infection morbidity in both adults and children, necessitating the development of new therapeutic options. Telavancin, an antibiotic approved in the United States for certain bacterial infections in adults, has not been examined in pediatric patients. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, John S., Goldman, Jennifer L., James, Laura P., Kaelin, Byron, Gibson, Breanne H. Y., Arrieta, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649008/
https://www.ncbi.nlm.nih.gov/pubmed/37815398
http://dx.doi.org/10.1128/aac.00987-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649008/
https://www.ncbi.nlm.nih.gov/pubmed/37815398
http://dx.doi.org/10.1128/aac.00987-23

Ejemplares similares